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Drug‑responsive autism 
phenotypes in the 16p11.2 deletion 
mouse model: a central role 
for gene‑environment interactions
Emma J. Mitchell1, David M. Thomson1, Rebecca L. Openshaw2, Greg C. Bristow3,4, 
Neil Dawson3,5, Judith A. Pratt1,5 & Brian J. Morris2,5*
There are no current treatments for autism, despite its high prevalence. Deletions of chromosome 
16p11.2 dramatically increase risk for autism, suggesting that mice with an equivalent genetic 
rearrangement may offer a valuable model for the testing of novel classes of therapeutic drug. 
16p11.2 deletion (16p11.2 DEL) mice and wild‑type controls were assessed using an ethological 
approach, with 24 h monitoring of activity and social interaction of groups of mice in a home‑cage 
environment. The ability of the excitation/inhibition modulator N‑acetyl cysteine (NAC) and the 
5‑HT1B/1D/1F receptor agonist eletriptan to normalise the behavioural deficits observed was tested. 
16p11.2 DEL mice exhibited largely normal behaviours, but, following the stress of an injection, 
showed hyperlocomotion, reduced sociability, and a strong anxiolytic phenotype. The hyperactivity 
and reduced sociability, but not the suppressed anxiety, were effectively attenuated by both NAC and 
eletriptan. The data suggest that 16p11.2 DEL mice show an autism‑relevant phenotype that becomes 
overt after an acute stressor, emphasising the importance of gene‑environmental interactions in 
phenotypic analysis. Further, they add to an emerging view that NAC, or 5‑HT1B/1D/1F receptor agonist 
treatment, may be a promising strategy for further investigation as a future treatment.
Autism is extremely common, affecting males more than females (estimated to affect roughly 4/1,000 boys and 
1/1,000 girls)1,2, and characterised by communication difficulties, social dysfunction, and repetitive or restricted 
behaviour patterns, with a high rate of comorbid conditions such as anxiety. There are no available drug treat-
ments for autism. Development of improved treatments will only be enabled by increased understanding of the 
causes of the disease and how they impact on neurobiology, informed by better preclinical models of facets of 
the disease.
The genetic architecture of autism is  complex3. While a large number of common sequence variations increase 
disease risk, each has only a very small effect individually, and it is the cumulative burden of a range of risk, and 
protective, gene variants that underlies the aetiological mechanisms ultimately resulting in the manifestation 
of the common, sporadic disease. However, it is now clear that very rare copy number variants (CNVs), where 
small numbers of genes are present in one or three, rather than two, copies, substantially increase disease risk. 
For example, carriers of the deletions of the 16p11.2 locus have dramatically increased risk of autism-spectrum 
disorders (ASD) and also intellectual disability (8–40x)4–6. Interestingly, a high proportion of carriers of the 
corresponding 16p11.2 duplication develop schizophrenia, suggesting that studying the neurobiological impact 
of CNVs at this locus may be particularly informative. The 16p11.2 deletion is one of the most powerful genetic 
risk factors for  autism3.
Various drug classes have been tested in mouse models relevant to ASD, for efficacy in reversing behavioural 
deficits in social paradigms. These social paradigms typically involve placing unfamiliar pairs of rodents in a 
open
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novel environment (e.g. open field or 3 chambered apparatus) and recording their interactions over a short 
 timeframe7. These relatively simple, high-throughput tests involve separating an animal from its cage mates 
and placing it in an unfamiliar apparatus. This results in stress-associated social disruption, which in the case 
of genetically-modified animals may interact with the environmental stressor to reveal a phenotype. Hence the 
outcomes determined in this testing paradigm may reflect a gene-environmental interaction phenotype, rather 
than a basal phenotype caused by the  model8. While this is not necessarily a confound to the disease-relevance 
of the model, it is important to dissociate the phenotypes that arise directly from the genetic manipulation and 
those that arise in response to gene-environment interactions, as this offers new insight into the basis of disease 
symptoms and aetiology, and is important in the context of drug validation and therapeutic relevance.
Abnormal phenotypes in mouse models relevant to ASD have reportedly been improved by  statins9, Akt/
mTOR  inhibitors10, mGlu5 receptor negative allosteric  modulators11, mGlu5 receptor positive allosteric 
 modulators12,13, and GABA-B receptor  agonists14–16. However, these findings have not translated successfully to 
clinical  trials17–19; see  also20. The reasons for this are unclear, but arguably are more likely to relate to the question-
able translatability of the behavioural assays employed, rather than the construct validity of the genetic models.
In the specific case of mice engineered to reproduce the 16p11.2 deletion (16p11.2 DEL mice), behavioural 
deficits have reportedly been normalised by the GABA-B receptor agonist  baclofen21, a mGlu5 receptor negative 
 modulator22, a 5-HT2A receptor  antagonist23 and a 5-HT1B/1D/1F  agonist24. The possibility that serotonergic drugs 
might have therapeutic potential is strengthened by the report of decreased 5-HT turnover in 16p11.2 DEL 
 mice23, and that syntenic 16p11.2 deletion restricted to serotonergic neurones in mice is reportedly sufficient 
to decrease  sociability24. However, there is also considerable interest currently in the possibility that modifying 
the balance between glutamatergic excitation and GABAergic inhibition might be a productive strategy. Exci-
tation/inhibition (E/I) balance is thought to be disturbed in  autism25–27. Accumulating evidence suggests that 
it is also a feature of mouse models relevant to ASD, including 16p11.2 DEL  mice28 and neurexin1 knockout 
mice (Hughes et al., in press). Recent studies have begun to investigate the behavioural effects of agents such 
as the E/I modulator N-acetyl cysteine (NAC). NAC is primarily an anti-oxidant, but also stimulates the system 
Xc- cysteine-glutamate antiporter on glial cells, increasing extrasynaptic  glutamate29 and thereby facilitating 
stimulation of presynaptic mGlu2 receptors to inhibit glutamate release.
In this study, we assess the behaviour of 16p11.2 DEL mice in an ethological context, using an automated 
home cage monitoring system which permits group housed animals to be assessed simultaneously for social 
and locomotor behaviours, and where the impact of acute stress can be separated from baseline behavioural 
 responses30–33. In addition, we assess the ability of NAC, as compared to the 5-HT1B/1D/1F agonist eletriptan, to 
ameliorate the behavioural impact of the 16p11.2 deletion.
Methods and materials
Animals. Male mice hemizygous for the 0.44-Mb region of mouse chromosome 7, syntenic to the human 
16p11.2 deletion, were generated by Mills and  colleagues30 (Jackson Laboratory stock No. 013128), and back-
crossed onto a C57BL/6 N background to generate experimental mice. It is important to emphasise that, in con-
trast to some other reports using this genetic modification, the mice in this study have been back-crossed onto 
the C57BL/6 N background until they are effectively congenic. The 16p11.2 DEL mice, and littermate wild-type 
(WT) controls, were housed with litter mates in their home cages from weaning. This was to ensure a minimal 
impact from external environmental factors during the development period from weaning to adulthood which 
may have influenced their behaviour prior to exposure to the experimental stressor in adulthood. Animals were 
housed in cages of mixed or same-genotype as previous studies with this line have shown that a range of behav-
iours including social approach, same-sex social interactions, open field and anxiety-related behaviours were not 
affected by housing in mixed-genotype versus same-genotype  cages34, 35. Animals were housed under standard 
conditions, with food and water ad libitum. All work was approved by the University of Glasgow Animal Welfare 
and Ethics Review Board (AWERB) and conducted in accordance with the UK Animals (Scientific Procedures) 
Act 1986.
Home cage monitoring. 14 male mice (7 WT + 7 16p11.2 DEL) were housed in trios or pairs (2 cages 
of 2 16p11.2 DEL and 1 WT, 1 cage of 3 WT, 1 cage of 3 16p11.2 DEL, and 1 cage of 2 WT) under a reversed 
light/dark cycle (lights off at 10.00am). Genotypes and numbers in cages were imposed by the genotype/sex 
configuration of the original litters, to avoid fighting between unfamiliar males put together after weaning. Note 
that the presence of 2 rather than 3 mice in a cage does not affect locomotor or anxiety measures (e.g. Supple-
mentary Fig. S1). Equally, there was no evidence that the behaviour of mixed genotypes in a cage differed from 
that of single genotypes (Supplementary Fig. S2). Under isofluorane anaesthesia, a radiofrequency identification 
(RFID) transponder was implanted subcutaneously into the lower left abdominal quadrant. Groups of 2–3 mice 
were then placed in Plexiglas IVC cages with Home Cage Analyser (Actual Analytics Ltd, UK)36,37 monitoring 
equipment. Mice were placed in the cages for 1.5 h prior to data acquisition to habituate. Recording then com-
menced at 10am and proceeded for 72 h. On days 3–5 of testing mice received the following treatments (within 
subjects counterbalanced design, i.p.): vehicle (50% PEG-400, 10% Solutol HS-15, 40%  dH2O), NAC (150 mg/
kg) and eletriptan (5 mg/kg). All drugs were administered intraperitoneally at an injection volume of 4 ml/kg, 
15 min prior to the onset of the dark period (09:45) (Fig. 1). Measures included: total distance travelled (mm), 
total number of antenna transitions, thigmotaxis, time in centre region of cage, separation (mean Euclidean 
distance to closest cage-mate (mm)) and social isolation (time spent > 100 mm apart from other cage-mates (s)).
Data analysis. For the measures of social behaviour (separation and isolation), data from pair-housed mice 
were excluded, as mice housed in pairs showed greater scores on these measures simply due to there being fewer 
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mice in the cage. Statistical significance was assessed by ANOVA (Minitab), with prior Box-Cox normalisation 
where data deviated substantially from normality. Mann–Whitney tests were used for specific planned com-
parisons between groups of particular interest. For the main hypothesised effects, figures also show effect size 
estimation (estimationstats.com), with mean differences shown as Gardner-Altman estimation  plots38,39, along 
with Bayes factors, estimated using  JASP40, with default (Cauchy) priors. JASP was used to estimate Bayes fac-
tors for t-tests (WT mice: vehicle treatment versus 16p11.2 DEL mice: vehicle treatment) or one way repeated-
measures ANOVA (16p11.2 DEL mice: vehicle treatment versus NAC treatment versus eletriptan treatment) 
with post-hoc testing. In all cases, Bayes factors proved to be robust against choice of priors (JASP). Bayes factor 
magnitudes were interpreted according to standard practice in life sciences  research41.
Results. Impaired social functioning is a key feature of autism, but there are limitations in capturing the 
complexity and multidimensional nature of this domain in rodent  models8, in part because standard paradigms 
involve elements of stress responsivity, as behaviour is monitored in a novel environment often between unfamil-
iar animals, over a limited time frame. We therefore monitored behaviours in group-housed mice in a home cage 
environment over 5 days33. Measures of locomotor activity and anxiety were monitored in parallel.
Basal locomotor and social activity (habituation, days 1–2). Both WT and 16p11.2 DEL animals 
exhibited normal circadian activity whereby their active phase was during the dark period (Fig. 2A). Mice were 
significantly more active during the dark phase versus light phase (F(1, 27) = 34.50; p < 0.0001) but there was no 
Figure 1.  Schedule of home-cage monitoring and drug administration. Days are numbered from introduction 
to experimental home cage. Dark and light bars represent 12 h dark and light phases. Drugs (vehicle, NAC or 
eletriptan) were administered in a counterbalanced design on days 3–5, at onset of dark period.
Figure 2.  Locomotor activity and isolation from cage-mates during first 2 days. (A) Circadian pattern of LMA 
over days 1–2. Results are shown as mean + /− s.e.m. for 15 min time bins. (B) Total LMA shown over days 1 
and 2 in dark and light phases. Difference between phases: (F(1, 27) = 34.50; p < 0.0001). (C) Circadian pattern 
of isolation over days 1–2. Results are shown as mean + /− s.e.m. for 15 min time bins. (D) Total isolation shown 
over days 1 and 2 in dark and light phases. Difference between phases: (F(1, 27) = 5.30; p = 0.03). Box plots show 
interquartile range with “Tukey” whiskers.
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genotype effect (p = 0.63) (Fig. 2B). This finding is in slight disagreement with previous authors: Horev et al.,30 
reported mild hyperactivity in DEL animals when placed in novel environment and Arbogast et al.,31 reported 
increased ambulatory activity in DEL mice during the dark phase.
16p11.2 DEL mice showed few signs of social impairment under baseline conditions. Time spent isolated 
(> 100 mm from all cage-mates) was significantly reduced during the light versus dark phase (F(1, 27) = 5.31; 
p = 0.03) and this was expected, as mice tend to sleep together when the lights are on (Fig. 2C). There was no 
overall effect of genotype (p = 0.78) (Fig. 2D).
There was no evidence that the effects of being moved to the monitoring cage had any interaction with geno-
type. Both WT and 16p11.2 DEL mice were more active in the first hour after being moved to the monitoring 
cage, as compared to the equivalent first hour of dark phase on the second habituation day (Supplementary 
Fig. S3). However, there was no evidence that this, or any of the other behavioural measures, was affected by 
genotype (Supplementary Fig. S3).
Drug treatment (days 3–5). The lack of previously reported hyperlocomotor and reduced sociability phe-
notypes, under home-cage monitoring conditions, prompted us to examine the response to an acute stressor 
(handling and injection).
Locomotor activity. Following injection of vehicle, the distance moved by 16p11.2 DEL mice was substan-
tially greater than that of WT controls for 30–45 min, supporting a stress-induced hyperlocomotor phenotype 
in these animals (Fig. 3A). By the end of an hour, the increased activity had subsided back to control levels 
(Fig. 3A). There was no effect of genotype on activity 60–120 min after injection (Supplementary Fig. S4). The 
elevated activity immediately following injection in 16p11.2 DEL mice was almost completely suppressed when 
the injection contained either NAC or eletriptan (Fig. 3A–D). Neither NAC nor eletriptan injection modified 
locomotor activity significantly in WT mice.
When we analysed a different measure of locomotor activity—the number of transitions between different 
sectors of the home cage, the increased activity in the 16p11.2 DEL mice was less clear (Supplementary Fig. S5), 
but the effect of the drugs to restore behaviour towards the control condition was still evident (Supplementary 
Fig. S5).
We also analysed behaviours thought to be related to anxiety—thigmotaxis, and time spent in the centre 
region of the home cage. Following the injection of vehicle, 16p11.2 DEL mice showed a very clear anxiolytic 
response, as demonstrated by significantly decreased thigmotaxis, and increased total time in the centre of the 
cage (Fig. 4A,B,D,E). The inhibitory effect of the drugs was less clear here, with no strong evidence that they were 
able to normalise the responses (Fig. 4A,C,D,F). In addition, both drugs did not modify anxiety-like behaviour 
in WT mice.
When we analysed measures of sociability—the mean separation between mice in the home cage, and the time 
spent isolated from other mice in the home cage, there was a trend towards reduced sociability in the 16p11.2 
mice. The effect of the drugs to restore behaviour towards the control condition was still evident (Fig. 5). Inter-
estingly, eletriptan showed a trend towards increasing isolation in WT mice, that was significant in the  2nd hour 
after injection (Supplementary Fig. S4).
Discussion
A number of previous reports have documented hyperactivity, increased or reduced anxiety, and unchanged or 
reduced sociability, in 16p11.2 DEL  mice21,30,31,42,43. In all cases, assessments have been made under conditions 
of some stress to the mice—with the tests involving experimenter handling, exposure to a novel environment, or 
injection, or social separation or exposure to unfamiliar conspecifics, depending on the task. Hence the resulting 
phenotype of the previous data potentially represents a combination of genetic and environmental factors. Here 
we delineate these factors by reporting the basal phenotypes in a relatively stress-free home-cage environment 
using a continuous monitoring system, and also the effect of an acute injection stressor, to parse these effects 
in the behavioural phenotypes seen in 16p11.2 DEL mice. In addition, we have characterised the ability of two 
drugs of interest with respect to future therapeutic options for autism—NAC and eletriptan—to normalise the 
stress-induced phenotypes observed in 16p11.2 DEL mice, showing dissociable effects on hyperactivity, anxiety-
like behaviour and sociability. Both NAC and eletriptan are rapidly absorbed in rodents and other  species44–46, 
allowing the assessment of their effects on the post-injection phenotypes observed. Both drugs are also com-
pletely cleared by 24 h after  administration44,46,47, so no carry-over effects are expected in our counter-balanced 
repeated measures design.
The within subjects, counterbalanced, repeated measures design is a strength of our study, allowing reductions 
in sample size while maintaining statistical power. For example, a retrospective power analysis from the social 
isolation data obtained, using  Glimmpse48, estimated a power of 0.83 to detect a genotype x drug interaction 
at p < 0.05 by ANOVA. Further, in accordance with recent and evolving  recommendations38,39,49, we include 
information on the confidence intervals for the main effects, and also some preliminary Bayesian analysis. The 
use of Cauchy priors for the Bayesian analysis might be seen as over-conservative, considering the previous 
reports of hyperactivity and hyposociability phenotypes in 16p11.2 DEL  mice21,30,31,50. While our results clearly 
align with these previous reports, due to the novel use of ethological behaviours in this study, we preferred to 
regard the results as entirely distinct from previous work, although in fact the Bayes factors obtained turned out 
to be relatively robust against varying the prior odds. For example, for the social measures in vehicle-injected 
mice (separation distance and isolation time), an informed prior based on existing literature with this genetic 
 mutation30,31,43 (mean 1.0, std 0.307) yields BF10 values of 3.6 and 3.8 respectively (moderate evidence for a 
genotype effect).
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We have examined the effect of an acute stressor in this study. It will be of great interest in future work to 
compare the effects of some of the widely-used chronic stress models on the phenotype of this and other mouse 
genetic models of aspects of ASD.
Comparison with previous research in 16p11.2 DEL mice. The original report of this strain dem-
onstrated a transient increase in locomotor activity relative to controls, lasting for less than 2 h after transfer 
to a novel  environment30. This seems broadly equivalent to our current observations. From testing in a novel 
environment and/or after an injection, others have observed rather subtle  hyperlocomotion21,31,42,43, no obvious 
locomotor  phenotype23,50, or decreased locomotor  activity51 in 16p11.2 DEL mice. In another study, Portman 
et al.35 reported increased home cage activity and decreased activity in a novel environment. The reasons for this 
variability are not clear, although many of these studies used mice maintained on a mixed background, which 
inevitably leads to increased variability in complex behaviours. It may also be an indication that this phenotype 
Figure 3.  Locomotor activity (distance moved) during first 60 min after injection at start of dark phase on 
days 3–5. (A) Data shown for 15 min time bins. Effect of genotype: (F(1, 167) = 0.02; p = 0.88); effect of drug 
treatment: (F(1, 167) = 6.49, p = 0.002; genotype x drug interaction: (F(1, 167) = 12.77, p < 0.001; (B)–(D) 
Locomotor activity over 60 min after injection on days 3–5. (B) Total distance moved: Effect of genotype: (F(1, 
167) = 0.02; p = 0.88); effect of drug treatment: (F(1, 167) = 6.49, p = 0.002; genotype x drug interaction: (F(1, 
167) = 12.77, p < 0.001. (C) The mean difference for total distance moved in 60 min following vehicle injection 
between WT and 16p11.2 DEL mice, plotted as a bootstrap sampling distribution. The Bayes factor for the 
alternative hypothesis  (BF10) of a difference between the vehicle-treated groups, is also shown. (D) The mean 
difference for NAC compared to vehicle, and eletriptan compared to vehicle, groups, in 16p11.2 DEL mice 
only, are shown in the above Cumming estimation plot. The mean difference is plotted as a bootstrap sampling 
distribution. The Bayes factors  (BF10) are also shown for one-way ANOVA of data from 16p11.2 DEL mice (left) 
(blue shading emphasises strong evidence for an overall effect of drug treatment), and for post-hoc tests of NAC 
vs vehicle (middle) and eletriptan vs vehicle (right). In all cases, Box plots show interquartile range with “Tukey” 
whiskers. For effect size plots, the mean difference is depicted as a dot; the 95% confidence interval is indicated 
by the ends of the vertical error bar. ~p < 0.05, ~~p < 0.01 vs corresponding vehicle group, same genotype, same 
time bin (post-hoc Tukey test).
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is rather subtle. Our data suggest a primary role in the interaction between environmental stress and the 16p11.2 
DEL genotype that may also contribute to the variability of these phenotypes under different environments. 
Interestingly, the corresponding mice with a duplication of the same region show a hypolocomotor phenotype, 
both in home cage and in a novel  environment30,31,52. Hence if there is a gene dosage effect in this phenotype, the 
16p11.2 DEL mice would be predicted to show elevated activity. We indeed detect increased locomotor activity 
after an acute stressor, although the effect is transient (Fig. 3). This emphasises the extent to which particular 
details of behavioral testing procedures (i.e. degree of environmental stressor) can influence the results obtained. 
Furthermore, the data highlight the fundamental need for the application of emerging behavioural testing strat-
egies, such as those used in this study, that allow for the parsing of genetic and environmental factors in the 
context of determining translationally-relevant phenotypes in genetic mouse models relevant to neurodevelop-
mental disorders.
While we detect genotype effects on locomotion and anxiety measures, the less clear effects of genotype on 
sociability measures suggest that reduced sociability is a less overt phenotype associated with 16p11.2 deletion. 
Indeed, most of the previous studies failed to detect altered social behaviours in 16p11.2 DEL mice (using a 
novel environment, 3 chamber test)30,31,35,43. Other studies have detected social dysfunction, albeit using mice 
on a mixed  background21,50. Our data are indicative of subtle social dysfunction that is revealed under condi-
tions of acute stress. Importantly, assessing social interaction between littermates in the home cage environment 
allows us to characterise sociability in the ethological context of established social hierarchies that exist between 
mice rather than the sociable behaviour displayed in the context of a novel social interaction with an unfamiliar 
Figure 4.  Anxiety measures [thigmotaxis—(A)–(C)—and time in centre—(D)–(F)] during first 60 min after 
injection at start of dark phase. (A) Thigmotaxis: Effect of genotype: (F(1, 167) = 3.60; p = 0.06); effect of drug 
treatment: (F(1, 167) = 0.14, p = 0.87; genotype x drug interaction: (F(1, 167) = 2.29, p = 0.11; ## p = 0.003 vs 
corresponding WT group (one-sided Mann Whitney test). (B) The mean difference for thigmotaxis in 60 min 
following vehicle injection between WT and 16p11.2 DEL mice, plotted as a bootstrap sampling distribution. 
The Bayes factor for the alternative hypothesis  (BF10) of a difference between the vehicle-treated groups, is also 
shown. Green shading emphasises very strong evidence for an effect of genotype. (C) The mean difference in 
thigmotaxis for NAC compared to vehicle, and eletriptan compared to vehicle, groups, in 16p11.2 DEL mice 
only, are shown in the above Cumming estimation plot. The mean difference is plotted as a bootstrap sampling 
distribution. The Bayes factors  (BF10) are also shown for one-way ANOVA of data from 16p11.2 DEL mice (left), 
and for post-hoc tests of NAC vs vehicle (middle) and eletriptan vs vehicle (right). (D) Total time in centre zone: 
Effect of genotype: (F(1, 167) = 3.65; p = 0.058); effect of drug treatment: (F(1, 167) = 1.26, p = 0.29; genotype x 
drug interaction: (F(1, 167) = 3.38, p = 0.037; ## p = 0.003 vs corresponding vehicle group, same genotype (one-
sided Mann Whitney test). (E) The mean difference for time in centre in 60 min following vehicle injection 
between WT and 16p11.2 DEL mice, plotted on the right as a bootstrap sampling distribution. The Bayes factor 
for the alternative hypothesis  (BF10), of a difference between the vehicle-treated groups, is also shown. Green 
shading emphasises very strong evidence for an effect of genotype. (F) The mean difference for time in centre, 
for NAC compared to vehicle, and eletriptan compared to vehicle, groups, in 16p11.2 DEL mice only, are shown 
in the above Cumming estimation plot. The mean difference is plotted as a bootstrap sampling distribution. The 
Bayes factors  (BF10) are also shown for one-way ANOVA of data from 16p11.2 DEL mice (left),and for post-hoc 
tests of NAC vs vehicle (middle) and eletriptan vs vehicle (right). In all cases, Box plots show interquartile range 
with “Tukey” whiskers. For effect size plots, the mean difference is depicted as a dot; the 95% confidence interval 
is indicated by the ends of the vertical error bar.
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conspecific (as employed in the 3 chamber test). As mice usually display higher levels aggression in the context 
of novel social interactions, with lower levels in the context of established hierarchies in the home cage, the 
potentially confound of this stressor is removed by home cage monitoring of littermate sociability. Future stud-
ies will allow the application of both the home cage and 3 chamber social testing paradigms to assess the role of 
stress and social familiarity in the sociability deficits seen in 16p11.2 DEL, and in other mouse models relevant 
to autism. It will be of interest to investigate whether exposure to alternative /more sustained stressors produces 
a larger impact on the social deficits observed.
In terms of the anxiolytic phenotype, other studies of 16p11.2 DEL mice have reported decreased  anxiety21,31,43, 
no  change42,50 or increased  anxiety51. Again this lack of consistency may at least partially reflect the use of mice 
on a mixed background in many cases, or the interaction between different stressors in the induction of this 
phenotype, as supported by our own findings.
Contribution of individual genes within the 16p11.2 region. There is a paucity of information con-
cerning the influence of specific genes within the 16p11.2 CNV on behaviour. Kctd13 gene knockout in mice 
reportedly does not affect locomotion, anxiety or social  behaviour53. However, mice with a genetic deletion 
specifically of the Taok2 gene exhibit hyperactivity and reduced anxiety in a novel  environment54. Hence it 
seems likely that Taok2 gene haploinsufficiency contributes to these phenotypes observed in the current study, 
especially since reduced JNK signalling (the downstream target of TAOK2) also decreases anxiety and increases 
Figure 5.  Social interaction measures [distance of separation—(A)–(C)—and time spent isolated—(D)–
(F)] during first 60 min after injection at start of dark phase. (A) Total separation: Effect of genotype: (F(1, 
143) = 0.18; p = 0.67); effect of drug treatment: (F(1, 143) = 0.91, p = 0.41; genotype x drug interaction: (F(1, 
143) = 3.14, p = 0.047. (B) The mean difference for separation in 60 min following vehicle injection between 
WT and 16p11.2 DEL mice, plotted as a bootstrap sampling distribution. The Bayes factor for the alternative 
hypothesis  (BF10) of a difference between the vehicle-treated groups, is also shown. (C) The mean difference 
for separation for NAC compared to vehicle, and eletriptan compared to vehicle, groups, in 16p11.2 DEL mice 
only, are shown in the above Cumming estimation plot. The mean difference is plotted as a bootstrap sampling 
distribution. The Bayes factors  (BF10) are also shown for one-way ANOVA of data from 16p11.2 DEL mice (left), 
and for post-hoc tests of NAC vs vehicle (middle) and eletriptan vs vehicle (right); red shading emphasises 
moderate evidence for an effect of NAC. (D) Time isolated: Effect of genotype: (F(1, 143) = 0.61; p = 0.44); effect 
of drug treatment: (F(1, 143) = 0.70, p = 0.50; genotype x drug interaction: (F(1, 143) = 6.96, p = 0.001; ~~p < 0.01 
vs corresponding vehicle group, same genotype (post-hoc Tukey test). (E) The mean difference for time spent 
isolated in 60 min following vehicle injection between WT and 16p11.2 DEL mice, plotted on the right as a 
bootstrap sampling distribution. The Bayes factor for the alternative hypothesis  (BF10), of a difference between 
the vehicle-treated groups, is also shown. (F) The mean difference for time isolated NAC compared to vehicle, 
and eletriptan compared to vehicle, groups, in 16p11.2 DEL mice only, are shown in the above Cumming 
estimation plot. The mean difference is plotted as a bootstrap sampling distribution. The Bayes factors  (BF10) are 
also shown for one-way ANOVA of data from 16p11.2 DEL mice (left), and for post-hoc tests of NAC vs vehicle 
(middle) and eletriptan vs vehicle (right). In all cases, Box plots show interquartile range with “Tukey” whiskers. 
For effect size plots, the mean difference is depicted as a dot; the 95% confidence interval is indicated by the ends 
of the vertical error bar.
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 locomotion55,56. Increased locomotor activity is seen in Mapk3 knockout  mice57,58, so decreased ERK1 activity 
due to hemi-deletion of the Mapk3 gene in 16p11.2 DEL mice may also contribute to the hyperlocomotor phe-
notype.
Restorative effects of NAC. Perturbed E/I balance is thought to be a core neurobiological feature of 
 autism25–27, detectable also in various genetic mouse models of  autism28. Indeed, optogenetic correction of E/I 
balance restores normal locomotor and social behaviour in CNTNAP2 knockout mice, another mouse genetic 
model of aspects of  autism59. In vitro studies suggest increased E/I ratios in hippocampus from 16p11.2 DEL 
 mice60, as do in vivo studies in cerebral  cortex28. Our data illustrate an ability of acute NAC administration, at a 
dose previously shown to reduce CNS glutamate  levels61, to attenuate the increased locomotor response to injec-
tion seen in the 16p11.2 DEL mice. This is quite a striking result, and may reflect a strong link between E/I balance 
and locomotor activity, since system Xc–deficient mice (system Xc- being the target of NAC) show abnormal 
 locomotion62. While a trend for NAC to attenuate the reduced sociability of 16p11.2 mice was observed, no effect 
of NAC was detected on the reduced anxiety-like behaviour manifest by these mice. A previous study reported 
that the same dose of NAC in mice decreases locomotion, and increases anxiety-like behaviour (decreased cen-
tre time in open field)61, while Xc–deficient mice show reduced anxiety, as reflected in increased centre time in 
the open field  arena62. The lack of effect of NAC on anxiety measures in 16p11.2 DEL mice is slightly surprising 
in that context. It may be that the mechanisms underlying the reduced anxiety, which is not considered a core 
symptom of ASD, are distinct from those underlying the reduced sociability and the increased locomotor activ-
ity. Alternatively, the beneficial effects of NAC may not be due to lowering of glutamatergic activity. Abnormal 
ERK and CREB activity is a feature of many autism-related mouse models, and also of some  patients63–65, and 
NAC can modulate this pathway  effectively66, in addition to its well-known anti-oxidant properties.
Whatever the mechanisms involved, our data support further investigation of NAC in preclinical models of 
autism. Small scale clinical studies have noted some improvements in individuals with ASD with NAC, including 
potential effects on stereotypies and social  cognition67,68.
Restorative effects of eletriptan. Panzini et al. reported evidence for decreased 5-HT turnover in the 
CNS of 16p11.2 DEL  mice23, suggesting that serotonergic hypofunction may contribute to the phenotypes seen 
in these animals. Therefore we tested the ability of the 5-HT1B/D/F agonist to restore these deficits. We found that 
eletriptan treatment effectively reversed the stress-induced hyperactivity seen in 16p11.2 DEL mice with no 
effect on the stress-induced reduced anxiety-like and sociability deficits seen in these animals.
5-HT1B agonists increase mouse locomotor activity (although locomotion is essentially normal in 5-HT1B 
receptor knockout mice)69. We saw a trend for eletriptan to increase locomotion in WT mice (Fig. 3A). Our 
evidence that eletriptan could suppress the hyperlocomotion observed after injection in the 16p11.2 DEL mice 
was clear. In view of the tendency for 5-HT1B agonists to enhance locomotion in WT mice, this is more likely to 
reflect an action of the drug on 5-HT1D or 5-HT1F receptors, neither of which are well-studied in terms of their 
behavioural effects in rodents.
5-HT1B knockout mice do however show reduced thigmotaxis in an open  field69. Consistent with this, 
5-HT1B/1D agonists are generally considered to be anxiogenic, so the greatest efficacy of eletriptan was expected 
to be seen in the anxiolytic phenotype. However, we saw little evidence for an anxiogenic effect of eletriptan in 
WT mice (Fig. 4A,B), or of an ability to normalise the anxiolytic phenotype observed after an injection in the 
16p11.2 DEL mice, indicating a more complex role for eletriptan in anxiogenesis.
It was interesting to note that eletriptan increased social isolation in WT mice in the 2nd hour after injec-
tion (Supplementary Fig. S4)—a time when eletriptan will still be present in the  CNS44. This is to some extent 
expected, as 5-HT1B/1D agonists increase social fear in rodents and  humans70,71, but the effect is not observed in 
16p11.2 DEL mice. Syntenic 16p11.2 deletion restricted to serotonergic neurones in mice reportedly decreases 
sociability—an effect that can be rescued by stimulation of 5-HT1B  receptors24. The present finding of an ability 
of electriptan to alleviate a social behavioural deficit in 16p11.2 DEL mice suggests further investigation of 5-HT 
subtype specific agonists in ASD is warranted.
Conclusions
Clinically, the appearance and exacerbation of autistic symptoms are associated with acute or chronic  stress72–74. 
An acute stress revealed locomotor, anxiolytic and impaired social behaviours in 16p11.2 DEL mice, that were not 
present under low stress conditions, suggesting that environmental factors such as stress interact with the genetic 
variant to reveal a disorder-relevant phenotype. Autistic subjects however tend to be hyperanxious rather than 
the  opposite75, so the translational significance of the anxiolytic response seen in 16p11.2 DEL mice is unclear. 
NAC and eletriptan showed intriguing efficacy to attenuate the more disease-relevant responses. Our data sup-
port evolving concepts that the correction of an unbalanced relationship between excitation and inhibition in 
the CNS, or, most strikingly, stimulation of 5-HT1B/1D/1F receptors to counteract serotonergic hypofunction, 
could be important future therapeutic strategies. In particular these data are important in a translational context 
given that drug-effectiveness was revealed in conditions where a stressor impacted on the behavioural outcome.
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